SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced ...
A webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 30 days.
Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or ...
A new CRISPR-based one-off procedure that lowers "bad" cholesterol has been approved to enter Phase I human trial. If ...
IEEE Spectrum on MSN
AlphaGenome deciphers non-coding DNA for gene regulation
Deep-learning model decodes the regulatory effects of DNA changes ...
Krystal Biotech reports positive clinical data for KB408 and KB407, demonstrating safety and efficacy in AATD and cystic fibrosis patients. Krystal Biotech, Inc. has announced promising clinical ...
Researchers at the Jackson Laboratory (JAX), the Broad Institute of MIT and Harvard, and Yale University, have used artificial intelligence (AI) to design thousands of new DNA switches that can ...
Single cell gene expression studies often rely on single-cell RNA sequencing (scRNA-seq) alone. While scRNA-seq reveals which genes are turned on, it does not capture protein expression or changes to ...
The company, founded by UC Berkeley scientists including Jennifer Doudna, is preparing to test its lead candidate STX-1150 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results